For our primary outcome, SGLT2 inhibitors reduced composite CV outcome comprising CV death or HHF or urgent visit for HF (hazard ratio [HR]: 0.80, 95% confidence interval [95%CI]: 0.74–0.86, prediction interval: 0.72–0.89; Figure 3A). This evidence concerns the gene SLC5A2 and hydrops fetalis.